Obesity
📧 Sign up to get email alerts when something new happens for Obesity.
Sign up freeTop drugs studied for this disease
-
EMA safety_alert · 2025-09-03Warning about sharp rise in illegal medicines sold in the EU
EMA warns that illegal medicines marketed as GLP-1 receptor agonists for weight loss and diabetes are circulating in the EU, posing serious …
-
EMA safety_alert · 2025-06-06Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 June 2025
EMA's PRAC concluded the safety review of semaglutide medicines and started a safety review of two chickenpox vaccines.
-
EMA safety_alert · 2025-01-17Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 January 2025
The EMA's Pharmacovigilance Risk Assessment Committee discussed an investigation into a rare eye condition potentially associated with semag…
-
EMA safety_alert · 2024-07-26EMA advises about risks of using weight loss medicine Mysimba with opioids
The EMA warns that combining Mysimba (naltrexone/bupropion) with opioid medicines can cause serious safety risks, and people should avoid or…
-
CLINICAL_TRIALS safety_alert · 2016-10-18Clinical Trial Update: Antibiotic-related Serious Adverse Events in Obese Patients Treated for Bone and Joint Infection
Clinical trial update reports antibiotic-related serious adverse events in obese patients treated for bone and joint infection, signaling sa…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA safety_alert · 2012-02-16European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines
EMA confirms that orlistat-containing medicines have a positive benefit–risk balance and are kept available, with ongoing monitoring of safe…
-
EMA safety_alert · 2011-09-22European Medicines Agency starts review of orlistat-containing medicines
EMA has initiated a review of medicines containing orlistat to assess safety and quality concerns.
-
EMA safety_alert · 2009-12-18European Medicines Agency updates on ongoing safety review of sibutramine: Weight-loss medicine assessed over cardiovascular concerns
The EMA provides updates on ongoing safety review of sibutramine, a weight-loss medicine, focusing on cardiovascular concerns.